Cheng Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cheng Cheng has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Chengcheng Liu
Fudan University
1 shared publication - Ching-Hon Pui
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
1 shared publication - Christian A. Fernandez
Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, United States
1 shared publication - Colton Smith
Hematological Malignancies Program and Center for Precision Medicine in Leukemia, St. Jude Children’s Research Hospital, Memphis, USA
1 shared publication - Dan Liu
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China
1 shared publication - Dan M. Roden
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
1 shared publication
Latest Publications
- 23 December 2023
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 76 (2) , 187-195
Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Meta-Analysis
Methanol with 12.5 wt% H2 content is widely considered a liquid hydrogen medium. Taking into account water with 11.1 wt% H2 content, H2 synthesis from the mixture of water and methanol is a promising method for on-demand hydrogen production. We demonstrate an atomic-level catalyst design strategy using the synergy between single atoms and nanodots for H2 production. The PtCu–TiO2 sandwich photocatalyst achieves a remarkable H2 formation rate (2,383.9 µmol h–1) with a high apparent quantum efficiency (99.2%). Furthermore, the oxidation product is a high-value chemical formaldehyde with 98.6% selectivity instead of CO2, leading to a nearly zero-carbon-emission process. Detailed investigations indicate a dual role of the copper atoms: an electron acceptor to facilitate photoelectron transfer to Pt, and a hole acceptor for the selective oxidation of methanol to formaldehyde, thus avoiding over-oxidation to CO2. The synergy between Pt nanodots and Cu single atoms together reduces the activation energy of this process to 13.2 kJ mol–1. Liquid water reforming of methanol is a promising method for on-demand hydrogen production. An atomic-level catalyst design strategy, using synergy between single atoms and nanodots, is now shown to demonstrate a high quantum efficiency for hydrogen production.
- 23 December 2023
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 76 (2) , 187-195
Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Meta-Analysis
Methanol with 12.5 wt% H2 content is widely considered a liquid hydrogen medium. Taking into account water with 11.1 wt% H2 content, H2 synthesis from the mixture of water and methanol is a promising method for on-demand hydrogen production. We demonstrate an atomic-level catalyst design strategy using the synergy between single atoms and nanodots for H2 production. The PtCu–TiO2 sandwich photocatalyst achieves a remarkable H2 formation rate (2,383.9 µmol h–1) with a high apparent quantum efficiency (99.2%). Furthermore, the oxidation product is a high-value chemical formaldehyde with 98.6% selectivity instead of CO2, leading to a nearly zero-carbon-emission process. Detailed investigations indicate a dual role of the copper atoms: an electron acceptor to facilitate photoelectron transfer to Pt, and a hole acceptor for the selective oxidation of methanol to formaldehyde, thus avoiding over-oxidation to CO2. The synergy between Pt nanodots and Cu single atoms together reduces the activation energy of this process to 13.2 kJ mol–1. Liquid water reforming of methanol is a promising method for on-demand hydrogen production. An atomic-level catalyst design strategy, using synergy between single atoms and nanodots, is now shown to demonstrate a high quantum efficiency for hydrogen production.
- Open Access
- 1 January 2017
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2017, 1-5
Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies
Here we describe, to our knowledge, the first case where an evolution of mechanisms responsible for hypercalcemia occurred in undifferentiated thymic carcinoma and discuss specific management strategies for hypercalcemia of malignancy (HCM). Case Description. We report a 26-year-old male with newly diagnosed undifferentiated thymic carcinoma associated with HCM. Osteolytic metastasis-related hypercalcemia was presumed to be the etiology of hypercalcemia that responded to intravenous hydration and bisphosphonate therapy. Subsequently, refractory hypercalcemia persisted despite the administration of bisphosphonates and denosumab indicative of refractory hypercalcemia. Elevated 1,25-dihydroxyvitamin D was noted from the second admission with hypercalcemia responding to glucocorticoid administration. A subsequent PTHrP was also elevated, further supporting multiple mechanistic evolution of HCM. The different mechanisms of HCM are summarized with the role of tailoring therapies based on the particular mechanism underlying hypercalcemia discussed. Conclusion. Our case illustrates the importance of a comprehensive initial evaluation and reevaluation of all identifiable mechanisms of HCM, especially in the setting of recurrent and refractory hypercalcemia. Knowledge of the known and possible evolution of the underlying mechanisms for HCM is important for application of specific therapies that target those mechanisms. Specific targeting therapies to the underlying mechanisms for HCM could positively affect patient outcomes.
- 1 January 2017
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2017, 1-5
Open AccessHypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies
Here we describe, to our knowledge, the first case where an evolution of mechanisms responsible for hypercalcemia occurred in undifferentiated thymic carcinoma and discuss specific management strategies for hypercalcemia of malignancy (HCM). Case Description. We report a 26-year-old male with newly diagnosed undifferentiated thymic carcinoma associated with HCM. Osteolytic metastasis-related hypercalcemia was presumed to be the etiology of hypercalcemia that responded to intravenous hydration and bisphosphonate therapy. Subsequently, refractory hypercalcemia persisted despite the administration of bisphosphonates and denosumab indicative of refractory hypercalcemia. Elevated 1,25-dihydroxyvitamin D was noted from the second admission with hypercalcemia responding to glucocorticoid administration. A subsequent PTHrP was also elevated, further supporting multiple mechanistic evolution of HCM. The different mechanisms of HCM are summarized with the role of tailoring therapies based on the particular mechanism underlying hypercalcemia discussed. Conclusion. Our case illustrates the importance of a comprehensive initial evaluation and reevaluation of all identifiable mechanisms of HCM, especially in the setting of recurrent and refractory hypercalcemia. Knowledge of the known and possible evolution of the underlying mechanisms for HCM is important for application of specific therapies that target those mechanisms. Specific targeting therapies to the underlying mechanisms for HCM could positively affect patient outcomes.
- Open Access
- 6 December 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (21) , 367
Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis
Background Glucocorticoids are an essential component of current treatment regimens for childhood acute lymphoblastic leukemia (ALL), and are a component of treatment for many autoimmune and inflammatory conditions. A common therapy-related and dose-limiting toxicity in ALL is glucocorticoid-induced osteonecrosis (ON). The mechanism and underlying genetic basis of ON risk are likely multifactorial. Methods We performed the largest genome-wide association study (GWAS) of ON to date in 2285 children with ALL who were treated on the Children's Oncology Group (COG) AALL0232 frontline protocol for high risk B-lineage ALL. We also studied two validation cohorts: 361 children with ALL treated on the frontline St. Jude Total XV protocol for ALL, and 309 children and adults treated with corticosteroids for oncologic and non-oncologic indications in the Vanderbilt University Medical Center BioVU DNA repository. Single nucleotide polymorphism (SNP) genotyping was performed using Illumina and Affymetrix Human Gene Chip Arrays. Additional SNPs were imputed using 1000 Genomes as the reference genome with MaCH-Admix and IMPUTE2. Testing for association was performed by Cox proportional hazard and logistic regression, with meta-analysis across cohorts using Stouffer's Z-score method. Gene based and pathway analyses were performed using SNP-set Kernel Association Test (SKAT) and Ingenuity Pathway Analysis (IPA), respectively. Results In the discovery GWAS for AALL0232, adjusting for gender, age, ancestry and treatment, the SNP with the strongest association was at 9q31.1 (rs28584318, odds ratio [OR] = 2.00, P = 4.86 x 10-7), near the GRIN3A locus (glutamate [NMDA] receptor subunit 3A). The same SNP was validated in both the St. Jude and Vanderbilt cohorts after adjusting for covariates (OR = 1.81 and 2.26, P = 0.0734 and 0.0073 respectively). Overall, patients with the variant genotype at rs28584318 in 9q31.1 had a higher incidence of ON compared with those patients who did not: AALL0232, St. Jude Total XV and Vanderbilt BioVU (15.8% vs 9.7%, 21.8% vs. 20.4%, 35.6% vs 24.0%). In the meta-analysis with both discovery and validation cohorts combined, the SNP at 9q31.1 (P = 5.34 x 10-8), and an additional variant in GRIK1 (glutamate receptor, ionotropic, kainate, rs2154490 P = 7.24 x 10-7) were most associated with risk of ON. Pathway analysis of the genes implicated in the discovery and validation cohorts also identified the glutamate pathway as the top overlapping canonical pathway present in all three cohorts (COG AALL0232 P = 0.045; St. Jude Total XV P = 0.011; Vanderbilt P = 0.037). Conclusions These findings demonstrate an association between loci in the glutamate pathway and glucocorticoid-induced ON. The glutamate pathway could be linked to ON via several mechanisms, including that glutamate receptors are involved in the mechanical signaling of bone and regulation of osteoblasts and osteoclastogenesis, and are affected by glucocorticoids. That this pathway was also implicated in a non-ALL cohort suggests glutamate pathway variation may modulate risk for ON across a wide array of patients treated with glucocorticoids.
- 6 December 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (21) , 367
Open AccessGlutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis
Background Glucocorticoids are an essential component of current treatment regimens for childhood acute lymphoblastic leukemia (ALL), and are a component of treatment for many autoimmune and inflammatory conditions. A common therapy-related and dose-limiting toxicity in ALL is glucocorticoid-induced osteonecrosis (ON). The mechanism and underlying genetic basis of ON risk are likely multifactorial. Methods We performed the largest genome-wide association study (GWAS) of ON to date in 2285 children with ALL who were treated on the Children's Oncology Group (COG) AALL0232 frontline protocol for high risk B-lineage ALL. We also studied two validation cohorts: 361 children with ALL treated on the frontline St. Jude Total XV protocol for ALL, and 309 children and adults treated with corticosteroids for oncologic and non-oncologic indications in the Vanderbilt University Medical Center BioVU DNA repository. Single nucleotide polymorphism (SNP) genotyping was performed using Illumina and Affymetrix Human Gene Chip Arrays. Additional SNPs were imputed using 1000 Genomes as the reference genome with MaCH-Admix and IMPUTE2. Testing for association was performed by Cox proportional hazard and logistic regression, with meta-analysis across cohorts using Stouffer's Z-score method. Gene based and pathway analyses were performed using SNP-set Kernel Association Test (SKAT) and Ingenuity Pathway Analysis (IPA), respectively. Results In the discovery GWAS for AALL0232, adjusting for gender, age, ancestry and treatment, the SNP with the strongest association was at 9q31.1 (rs28584318, odds ratio [OR] = 2.00, P = 4.86 x 10-7), near the GRIN3A locus (glutamate [NMDA] receptor subunit 3A). The same SNP was validated in both the St. Jude and Vanderbilt cohorts after adjusting for covariates (OR = 1.81 and 2.26, P = 0.0734 and 0.0073 respectively). Overall, patients with the variant genotype at rs28584318 in 9q31.1 had a higher incidence of ON compared with those patients who did not: AALL0232, St. Jude Total XV and Vanderbilt BioVU (15.8% vs 9.7%, 21.8% vs. 20.4%, 35.6% vs 24.0%). In the meta-analysis with both discovery and validation cohorts combined, the SNP at 9q31.1 (P = 5.34 x 10-8), and an additional variant in GRIK1 (glutamate receptor, ionotropic, kainate, rs2154490 P = 7.24 x 10-7) were most associated with risk of ON. Pathway analysis of the genes implicated in the discovery and validation cohorts also identified the glutamate pathway as the top overlapping canonical pathway present in all three cohorts (COG AALL0232 P = 0.045; St. Jude Total XV P = 0.011; Vanderbilt P = 0.037). Conclusions These findings demonstrate an association between loci in the glutamate pathway and glucocorticoid-induced ON. The glutamate pathway could be linked to ON via several mechanisms, including that glutamate receptors are involved in the mechanical signaling of bone and regulation of osteoblasts and osteoclastogenesis, and are affected by glucocorticoids. That this pathway was also implicated in a non-ALL cohort suggests glutamate pathway variation may modulate risk for ON across a wide array of patients treated with glucocorticoids.